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REGULATORY T CELL PLASTICITY AND ITS ROLE IN THE REJECTION 
OF PANCREATIC ISLET ALLOGRAFT TISSUE 
 
JONATHAN E AKER 
ABSTRACT 
  
 The healthy immune system is a delicate and precisely orchestrated balance 
between activation and suppression. It is well established that regulatory T cells (Tregs) 
have substantial immunosuppressive properties and play a pivotal role in maintaining this 
balance. Many autoimmune states have been characterized by disproportionately high 
numbers of T effector cells, and comparatively low numbers of regulatory T cells (Hori et 
al., 2003;Sakaguchi et al., 1995;Choileain et al., 2006). Furthermore, mouse models in 
which regulatory T cells are removed or rendered ineffective show rapid development of 
autoimmunity. It is therefore hypothesized that regulatory T cells are essential to the 
acquisition and maintenance of self-tolerance.  
 Type 1 diabetes is an increasingly common autoimmune condition, with 30,000 
new diagnoses each year (JDRF Fact Sheet). Pancreatic islet transplantation holds great 
promise as a potential cure for this difficult disease; however human trials have had 
limited success. Attempts to promote self-tolerance or maintain a physical barrier to the 
transplanted islets have largely failed (Groot et al., 2004). Because of this, insulin 
dependence normally resumes fiver years post-operation. The deleterious effects of long-
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term immunosuppression to promote extended islet survival are considered too great to 
justify this treatment. 
 Because of their important role in promoting self-tolerance, many immunologists 
believe regulatory T cells are the key to developing tolerance of islet allograft tissue. 
Rapamycin and anti-CD154 are immunoregulatory treatments that specifically inhibit the 
activation of T effector cells and promote the growth of regulatory T cell populations. As 
regulatory T cell numbers increase, self-tolerance is established and the need for 
immunosuppressant drugs is eliminated.   
 Unfortunately, treatments such as anti-CD154 and rapamycin have had limited 
success due to the ability of toll-like receptor (TLR) pathways to bypass such activation 
blockades. TLR stimulation results in a potent and direct activation that acts to bolster the 
immune response. This TLR activation results in the release of inflammatory cytokines, 
which render regulatory T cells unstable. Regulatory T cells have been shown to adopt 
effector phenotypes in such environments and may have pathogenic potential.  
 This study aims to elucidate aspects of Treg plasticity that result from TLR 
activation. In vitro models were used to demonstrate how TLR agonists change Treg 
phenotypic expression. Our findings indicate that the presence of lipopolysaccharides 
(LPS) has a relatively significant effect on regulatory T cell phenotypes. Specifically, our 
findings indicate that LPS causes increased GATA3 expression in Tregs, promoting 
differentiation to a TH2 phenotype (p= 0.0543). Regulatory T cells were also examined 
for the expression of RORγt and Tbet transcription factors. Neither transcription factor 
was significantly expressed, indicating the absence of TH17 and TH1 phenotypes, 
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respectively. It is also worth noting that stability of the foxp3 transcript appeared to be 
greater in cells treated with LPS, than in those without (p= 0.0009).  
 In addition, this study utilized an in vivo model for tracking regulatory T cell 
changes after pancreatic islet transplantation. Diabetic reporter mice received pancreatic 
islet transplants, as well as TLR agonist to induce allograft rejection. Mice were treated 
with rapamycin, anti-CD154 and TLR agonist. After 12 days, regulatory and ex-
regulatory T cells were harvested from the transplanted area and analyzed. This 
experiment is still in progress and results have yet to be determined.   
 This study establishes proof of concept of an effective system for the study of 
regulatory T cell plasticity. Additional investigation must be done in order to more 
thoroughly understand these important cells. This study is not complete, but our progress 
thus far is a strong foundation for further experimentation.  
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INTRODUCTION 
 A fundamental function of the body’s immune system is to identify and destroy 
foreign matter that has pathogenic potential. To accomplish this, the human immune 
system relies on a complex array of signaling pathways to identify and destroy harmful 
matter.  Under certain circumstances, the immune system can become hypersensitive to 
healthy tissue. This leads to the unwanted destruction of necessary tissue, resulting in 
disease. This is the case in autoimmunity and transplant rejection. Under normal 
conditions, the immune system is kept in check by regulatory T cells (Tregs). Regulatory 
T cells play the pivotal role of down-regulating effector immune cell activity in order to 
prevent the destruction of healthy tissue. Cases in which the ratio of effector T cells to 
regulatory T cells is higher than normal have been shown to be associated with states of 
autoimmunity (Zhou et al., 2009;Bailey-Bucktrout et al., 2013). Furthermore, it has been 
well documented that the same phenomenon is found in tissue associated with transplant 
rejection. In contrast, when regulatory T cell are present in large quantities, 
immunosuppression and self-tolerance is observed (Sanchez-Fueyo et al., 2006). 
Regulatory T cells therefore help to maintain self-tolerance and prevent states of 
autoimmunity.   
 
Regulatory T Cells 
 While working at Yale University in the late1960’s, Dr. Richard Gershon 
identified what he believed to be a subset of T cells that exhibited immunosuppressive 
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characteristics (Shevach et al., 2011). These T suppressor cells failed to gain acceptance 
due to an inability to positively indentify their distinct population. The scientific 
community gradually lost interest in T suppressor cells until the early 1990’s when a 
distinct population of T cells was identified that produced large amounts of the 
immunosuppressive cytokine, interleukin 10 (IL-10) (Choileain et al., 2006). These cells 
were identified as CD4+CD25+ lymphocytes. It was not until Sakaguchi and his 
colleagues identified FoxP3 as an additional marker that regulatory T cells were accepted 
as a distinct T cell lineage (Choileain et al., 2006).  
 It has been demonstrated that a lack of CD4+CD25+ T cells leads to the onset of 
many autoimmune states, including type 1 diabetes, chronic gastritis, and rheumatoid 
arthritis (Hori et al., 2003;Sakaguchi et al., 1995;Choileain et al., 2006). In 2003 Hori et 
al were able to show that retroviral gene transfer of Foxp3 converted naïve T cells to a 
regulatory phenotype (Hori et al., 2003). Based on their data, Hori and colleagues 
hypothesized that Foxp3 is a key regulatory gene for the production and development of 
regulatory T cells. For years, immunologists have been hopeful that they might be able to 
use regulatory T cells as a way of naturally altering an individual’s immune system to 
favor a non-active state. Most of these efforts have failed due to the instability of 
regulatory T cells in vivo.  
 
The Danger Hypothesis  
 It has been well established that injection of a foreign antigen does not always 
promote an immune response. To explain this fact, it was hypothesized that our bodies 
	  3 
have ways of determining which foreign material has pathogenic potential and should be 
eliminated. In the 1920’s, Ramon and Glenny observed that a significant immune 
response is only observed in the presence of certain molecular patterns, which they called 
adjuvants (Kono et al., 2008). For decades, the question as to why these adjuvants were 
so effective went largely unexplored. It was not until the 1980’s that immunologists 
began to theorize how the immune system determines which foreign antigens present a 
danger to the body. In 1989, Janeway postulated that the APCs of the innate immune 
system recognize specific molecular patterns that have pathogenic potential (Kono et al., 
2008).  Janeway named these activation initiators pathogen-associated molecular patterns 
(PAMPs) and identified non-mammalian microorganisms as their source. 
 Subsequent experimentation has shown that Janeway’s hypothesis is largely 
correct; however, it fails to explain why primary and secondary cell necrosis triggers an 
immune response. Specifically, it did not account for the inflammation seen in post-
operative patients (ie.: transplantation). In 1994, Matzinger formulated a hypothesis 
meant to explain inflammation driven by non-apoptotic cell death (Kono et al., 2008). 
According to her hypothesis, during necrotic cell death, damage-associated molecular 
patterns (DAMPs) are released into the blood stream and trigger an immune response. 
Matzinger postulated that DAMPs act as a universal danger signal and can change the 
state of our immune system from stable to active. 
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Figure 1. Differentiating between normal and abnormal cell death.  On the left, immune cells 
recognize the presence of an apoptotic cell, but are not exposed to the encapsulated damage-associated-
molecular-patterns (DAMPs). Therefore no immune response is initiated. On the right side of the figure, 
necrotic cells are shown to release DAMPs, which interact with immune cells to initiate a response. (Figure 
taken from Kono et al., 2008) 
 
Matzinger’s danger hypothesis has since been validated and it is suspected to be a 
major reason that regulatory T cell therapy is not yet reliable to prevent transplant 
rejection. Even if donor and recipient are well matched, transplant rejection may occur 
due to cell death and the release of DAMPs after transplantation. The presence of 
DAMPs signals to the immune system that something is amiss. Cells of the immune 
system subsequently adopt the activated phenotype and have the unwanted effect of 
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destroying the allograft tissue. This is similar to an autoimmune state, in which there is an 
imbalance between regulatory immune cells and those that are in the active immune state.  
 
 
Implications of the Danger Hypothesis on Regulatory T Cell Phenotype 
Komatsu et al have shown that regulatory T cells differentiate into TH17 cells in 
arthritic conditions (Komatsu et al., 2014). Regulatory T cells that have differentiated to 
adopt an effector phenotype are broadly considered ex-regulatory T cells, or ExRegs. By 
having effector functionality, ex-regulatory T cells may contribute to the pathogenesis of 
the autoimmune condition. This finding suggests that under non-pathogenic conditions, 
there is a balance between the number of effector and regulatory T cells. If that balance 
shifts to favor the presence of relatively more effector T cells, then autoimmunity and 
transplant rejection occur. It has been postulated that blocking specific pathways 
necessary for the transition from a regulatory to effector phenotype would greatly 
increase the probability of successful tissue transplantation. In 2005, Peng and colleagues 
were able to show that activation of toll-like receptor 8 reversed regulatory T cell 
function, and promotes the effector phenotype (Peng et al., 2005).  
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Figure 2. Foxp3+ T cell differentiation into effector T cell phenotypes. Various inflammatory conditions 
have been shown to be associated with specific changes in Treg phenotypes. (Figure taken from Cretney et 
al., 2013) 
 
Furthermore, Peng concluded that regulatory T cell transdifferentiation is 
dependent on a functional TLR8-MyD88-IRAK4 signaling pathway in antigen presenting 
cells. In T cells, transdifferentiation has been shown to be dependent on several distinct 
transcription factors that control gene expression. For example, retinoic acid-related 
orphan receptor- γt (RORγt), T-bet, and GATA-binding protein-3 (GATA3) are known to 
be associated with controlling T cell function (Campbell et al., 2011). Activation of these 
transcription factors leads to the expression of the TH17, TH1, and TH2 cell phenotype, 
respectively. Conversely, transcription factors that block Treg differentiation have been 
identified as well. Examples include the signal transducer and activator of transcription 3 
(STAT3) and the interferon regulatory factor 4 (IRF4) transcription factors. These 
	  7 
transcription factors block the differentiation of Treg cells into TH17 and TH2 cells, 
respectively. These findings indicate that manipulating these pathways with small 
molecule ligands may have the potential to increase regulatory T cell stability and open 
the door for the possibility of regulatory T cell therapies.  
                 
Figure 3. Transdifferentiation of regulatory T cells into effector T cell phenotypes is blocked 
by STAT-3 and IRF-4 dependent mechanisms. Regulatory T cells functionality is maintained by various 
transcription factors. For example, STAT-3-dependent mechanisms block transdifferentiation of Tregs into 
TH17 cells, while IRF-4-dependent mechanisms block transdifferentiation into TH2 cells. Conversely, 
GATA3, RORγt, and T-bet transcription factors promote the conversion of Tregs into TH2, TH17, and TH1 
cells, respectively. (Figure taken from Campbell et al., 2011)  
 
Several cytokines released by antigen presenting cells (ie:. dentritic cells) have 
been identified in playing key roles in T cell transdifferentiation. Upon activation, T cells 
may adopt a number of different phenotypes, depending on the cytokines produced and 
where in the body the Treg is located. For instance, in the case of infection, the presence 
of TGF-β and Interleukin 6 will promote the expression of TH17 phenotypic expression 
(Campbell et al., 2011). On the other hand, IFNγ and interleukin 12 will direct a Treg to 
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differentiate into a TH1 effector T cell (Kohno et al., 1997). And finally, interleukin 4 is a 
potent inducer of the TH2 phenotype (Swain et al., 2011). 
Cytokines Phenotype Expressed 
TGF-B + IL-6 TH17 
IFN-y + IL-12 TH1 
IL-4 TH2 
Table 1. Different inflammatory environments promote the conformational change of regulatory T 
cells to effector phenotypes. ExRegs are made when regulatory T cells are exposed to an inflammatory 
environment. The new phenotypic identity of ExRegs is dependent on the cytokines present and the type of 
tissue where the Tregs are located. (Campbell et al., 2011)(Swain et al., 2011)(Kohno et al., 1997) 
 
In order for the phenotypic changes discussed above to occur naturally on a large 
scale, APC induced T cell activation must occur. The mechanism for this activation 
occurs in a stepwise fashion. The first step involves the classic model of T cell receptor 
(TCR) activation by the major histocompatibility complex (MHC) of an antigen 
presenting cell. At this point, T cell activation is relatively weak and further 
costimulation is necessary for a robust response. Binding of a CD154 surface protein on a 
T cell to its complementary CD40 ligand on the APC marks the completion of step two. 
CD154-CD40 binding results in a large increase in the expression of CD80 and CD86 
surface proteins on the antigen presenting cell. CD80 will then work in concert with 
CD86 to bind to the CD28 surface protein on a T cell. The APC will begin to produce 
and release an array of cytokines that cause phenotypic changes in the now activated T 
cell (T. Thornley, personal communication).  
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The three steps discussed above are generally needed for T cell activation. The 
exception occurs through direct activation via a toll-like receptor (TLR) agonist (Chen et 
al., 2006;Porrett et al., 2008). This has been of particular importance when attempting to 
induce tolerance by using blocking agents to prevent T effector cell activation. Therapies 
that utilize such mechanisms have had limited success due to the ability of TLR pathways 
to bypass CD40 activation and directly induce CD80/CD86 stimulation. Toll-like 
receptors bind to immunoreactive agents, such as lipopolysaccharides (LPS) and CpG 
oligodeoxynucleotides (CpG), and cause activation of downstream pathways leading to 
the production and release of cytokines (T. Thornley, personal communication).  
There are several toll-like receptor pathways that are worth mentioning. Most 
TLR pathways can be divided into two groups: MyD88-dependent and MyD88-
independent pathways. The MyD88-dependent pathway can associate with any TLR, 
except for TLR4, and is necessary for the production of inflammatory cytokines (Kaisho 
et al., 2006).  
MyD88 pathways generally require the recruitment of IL-1 receptor associated 
kinases (IRAK), which associate with TRAF and IKK, leading to the activation of the 
NF-κB transcription factor. NF-κB activation is associated with effector T cell 
phenotypes and leads to the production of several inflammatory cytokines. Alternatively, 
the MyD88-TRIF-IKK/TBK pathway used by TLR 4 activates the IRF3 transcription 
factor, resulting in the production of interferon-β (IFN-β) (Kaisho et al., 2006). IFN-β is 
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a cytokine that induces either immunoactivation or suppression, depending on the 
environment in which it is found (T. Thornley, personal communication).    
The second TLR pathway subset, the MyD88-independent pathway, is primarily 
involved in signaling for the production of interferon cytokines. The two most notable 
TLRs that utilize this pathway are TLR3 and TLR4. TLR3 associates directly with TRIF 
and ultimately induces activation of IRF3. TLR 4 also utilizes this TRIF-dependent 
pathway; however, it must first interact with a TRIF-related adapter molecule (TRAM) in 
order to do so (Kaisho et al., 2006).  
Toll-like receptors have been shown to have different type ligands depending on 
their positioning in the cell. For instance, toll-like receptors located in endosomes interact 
with single and double stranded DNA and RNA. These toll-like receptors, which include 
TLR3, TLR7, and TLR9, are typically involved in the immune response to viral infection 
and the presence of foreign DNA. CpG oligodeoxynucleotide (CpG), for example, is a 
single stranded DNA fragment that activates TLR3 and leads to the production of 
inflammatory cytokines. Toll-like receptors located on the cell surface generally ligate 
with proteins associated with bacteria (PAMPs) and necrotic debris (DAMPs). Toll-like 
receptors 1, 2, 4, 5, and 6 are several of those that fall under this category (Kaisho et al., 
2006). Lipopolysaccharides, an important protein associated with gram-negative bacteria, 
interacts with TLR4 and activates a NFκB transcription factor, leading to the production 
of inflammatory cytokines (Kaisho et al., 2006;T. Thornley, personal communication). 
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As mentioned earlier, activation of toll-like receptors results in pathways that 
bypass the three steps needed for T cell activation. LPS and CpG both utilize these 
bypass pathways and result in the production of inflammatory, and potentially pathogenic 
cytokines. For example, TLRs 3, 4, 7 and 9 will upregulate CD80/CD86 expression, 
bypassing the need for CD28-induced activation (T. Thornley, personal communication). 
Alternatively, activation of TLRs 1, 2, 4, 5 or 6 will lead to NFκB expression and directly 
induces the production of inflammatory cytokines. The implications that these bypass 
pathways have on the development of a drug to induce transplant tolerance are immense. 
Several therapies that are either currently used, or are being evaluated for potential use 
are worth mentioning.  
Current/Potential transplant therapies  
Anti-CD154 
CD154 is expressed on a variety of cell types (T cells, macrophages, antigen 
presenting cells, etc) and plays a major roll in the immunoactivation of T cells (Kirk et 
al., 2001). The three-step model mentioned earlier mediates T cell activation. According 
to this model, three steps are required for effective T cell activation. The first is generated 
from the binding of the T cell receptor to the major histocompatibility complex (MHC) 
ligand. Signal two is generated upon binding of CD154 on the T cell to its ligand, CD40, 
on an APC (Kirk et al., 2001). Binding of a T cell’s CD28 surface protein to its 
CD80/CD86 complement on the APC leads to the initiation of signal three, which causes 
the production and release of inflammatory cytokines (T. Thornley, personal 
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communication). When the TCR, CD154 and CD28 complexes are bound to their 
respective ligands, the T cell and APC are most active and will undergo processes to 
create a more robust immune response. Specifically, ligation of CD40 has been shown to 
upregulate expression of MHC II on antigen presenting cells, thereby enhancing their 
ability to interact with T cells (Kirk et al., 2001). Additional studies by this group have 
shown that CD154 binding increases expression of costimulatory molecules CD80 and 
CD86 on T cells. This increased expression promotes the ability of CD86 and CD80 to 
bind to its CD28 complement, which dramatically increases cytokine release. Anti-
CD154 is effective in blocking the binding and activation of the CD154 complex; thereby 
suppressing the immune response generated by APC-T cell binding. Specifically, anti-
CD154 blockade prevents signal three from occurring by inhibiting the upregulation of 
CD80/CD86 transcription factors (Porrett et al. 2008;Chen et al. 2006). In addition to 
blocking effector T cell activation, CD154 blockade has been associated with regulatory 
T cell expansion and the induction of permanent tolerance (Rigby et al., 2008). Although 
anti-CD154 has demonstrated enormous potential in both mouse and monkey models, it 
is currently not used in humans due to significant side effects.  
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-------------------------------------------------------------------------------------------------- 
 
Figure 4. Treatment with Anti-CD154 induces tolerance. A) The three-step model for T cell activation. 
TCR binding to MHC complex leads to increased expression of the CD154 surface molecule. CD154 then 
binds to CD40 on an APC, resulting in increased expression of the CD80/CD86 surface protein complex. 
This upregulation enables increased binding to the CD28 costimulatory molecule and T cell activation. B) 
Anti-CD154 induces tolerance by blocking CD40-CD154 interaction. This blockade prevents upregulation 
of the CD80/CD86 complex, inhibiting costimulation and T cell activation. (Figure taken from T. Thornley, 
2006) 
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Rapamycin 
 Rapamycin (RAPA) is an immunosuppressant commonly used in patients after 
kidney transplant due to its low toxicity towards the kidneys. Rapamycin acts as an 
immunosuppressant by blocking IL-2, IL-4, IL-7, IL-12, and IL-15-driven T cell 
proliferation (Sehgal, 1998). RAPA is also known to stop the cell cycle in the mid to late 
G1 phase (Sehgal, 1998). RAPA is the inhibitor of the mammalian target of rapamycin 
pathway (mTOR), thereby preventing T cell activation (Foster et al., 2010).  
 
Belatacept and Abatacept 
 Belatacept is a treatment designed to block the interaction of CD28 
of the T cell with its CD80/CD86 ligand on an APC. It accomplishes this through its very 
high affinity for the CD80/CD86 complex, thereby preventing the CD28 surface protein 
from gaining access to its compliment. Blockage of the CD80/CD86 complex prevents 
both the initiation of signal three, and the promotion of inflammatory cytokine release. 
This lack of stimulation results in T cell anergy and eventual apoptosis (Vincenti et al., 
2005;Vincenti et al., 2010).  
 Similar in structure to Belatacept, Abatacept also inhibits T cell activation via 
binding to CD80 and CD86. Abatacept is a fusion protein made from the extracellular 
portion of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and the constant region 
fragment of human immunoglobulin 1 (IgG1). CTLA4 is a surface protein found on T 
cells that binds to an APC and acts to downregulate immunoactivation. Abatacept mimics 
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this property of CTLA4 and promotes immunosuppression. Abatacept is highly 
efficacious in treating several autoimmune diseases, including rheumatoid arthritis and 
psoriasis. Abatacept, however, has had less success in promoting the acceptance of 
transplanted tissue. Belatacept is considered a much strong immunoregulator and has 
been much more successful in the transplant model (Genovese, 2005;Vincenti et al., 
2005).  
 
Successful transplantation is of pivotal importance in combating some of the most 
prevalent diseases. Type 1 diabetes (T1D), for example, affects 30 million Americans, 
with 30,000 new patients diagnosed each year (JDRF Fact Sheet). Islet Transplantation 
has been shown to be very effective in reversing T1D, with individuals remaining insulin 
independent for at least one year post-operation. Islet or whole pancreas transplantation is 
the closest treatment to a cure for T1D; however, these methods are seldom used 
clinically. Attempts to promote self-tolerance or maintain a physical barrier to the 
transplanted islets have largely failed (Groot et al., 2004). Because of this, insulin 
dependence normally resumes fiver years post-operation. The deleterious effects of long-
term immunosuppression to promote extended islet survival are considered too great to 
justify this treatment.  
Regulatory T cell therapies have great potential to maintain immunosuppression 
without compromising the health of the recipient. It has been well documented that Tregs 
are very effective in promoting immunosuppression, and are crucial to maintaining self-
tolerance. Several therapies, such as Belatacept and Anti-CD154, which are currently 
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used in humans or monkeys, have shown great potential in expanding regulatory T cell 
populations and promoting long-term tolerance. However, success with these drugs has 
been limited due to TLR activation and subsequent bypass of the T cell-stimulation 
blockade (Porrett et al., 2008). Continued investigation of these TLR pathways and their 
resulting cytokines is therefore of upmost importance. 
Reliable regulatory T cell expansion and the induction of tolerance has 
breakthrough potential in transplantation. Regulatory T cell therapies have further 
potential to correct states of autoimmunity. It is therefore of great importance that further 
efforts be made to better understand these cells. The goal of this research thesis is to 
elucidate how regulatory T cell phenotypes change in several different models of islet 
transplantation. Specifically, this project uses islet transplantation in mouse models to 
determine what types of regulatory T cell-derived phenotypes are expressed after 
transplant rejection. In addition, this study will investigate how TLR agonists affect 
regulatory T cell function and phenotype. ExRegs will be analyzed for which 
transcription factors are expressed, and which signaling molecules these cells may be 
producing. 
 
Specific Aims/Objectives 
 Regulatory T cells are known to have a great amount of plasticity in vivo. Treg 
phenotypes have been observed to change from having immunosuppressive to effector 
roles under certain conditions; however, regulatory T cell plasticity has yet to be 
thoroughly examined in pancreatic islet transplant models. The differentiation of Tregs 
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into effector T cells likely has major implications to the survival of allograft tissue. 
Therefore, the function of regulatory T cells in transplantation models has great clinical 
relevance and should be further investigated. 
The goal of the present study is to determine how regulatory T cell phenotype’s 
change after transplantation. Specifically, 
(1) What other T cell phenotypes (if any) are expressed in transplant tissue? The goal 
here is to determine what markers these cells express. For example TH17, TH2, 
TH1, etc.  
(2) In vitro studies will be conducted as well to identify any differences from the in 
vivo models that might be present. Consistencies between the in vivo and in vitro 
studies will strengthen to the results of this study. 
(3) Functional assays will be performed to determine that these ExRegs behave as 
their respective phenotypes do.  
a. What cytokines are ExReg cells producing, and how much of each? For 
example, do ExReg TH17 cells produce the same signaling molecules (ie.: 
IL-17) in the same quantity as those TH17 that are not ExRegs? 
b. This study will examine CD4+Foxp3+ T cells after exposure to PAMPs to 
determine if these cells still express the regulatory phenotype. We 
postulate that Foxp3 may still be expressed on the cells surface while 
transcription for this protein has been shut off. Therefore, the cell 
expresses the regulatory T cell phenotype while functionality may be 
similar to something in between a Treg and effector T cell.   
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(4) We hope to identify signaling pathways within regulatory T cells that are 
necessary for their conformational change into ExRegs. By identifying these 
mechanisms, our hope is that small molecule ligands might be identified that have 
the potential to block the Treg to ExReg change.  
 
This study’s purpose is to elucidate aspects of regulatory T cell plasticity in 
transplanted mouse models. The overarching goal of which is to provide information that 
might be useful in developing post-operative transplant therapies. Regulatory T cell 
therapies have the potential to dramatically increase rates of successful transplantation 
without the use of long-term immunosuppressive drugs. By doing so, transplantation will 
be more reliable, and the risk of complication will decrease.   
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METHODS 
  
The methods and materials used for this study were based on those proposed in a 
grant submitted to the National Institute of Health and the American Diabetes 
Association. Mice used were bred and stored in Beth Israel Deaconess Medical Center’s 
pathogen-free barrier facility. All regulatory guidelines set forth by Beth Israel Deaconess 
Medical Center and the Institution of Animal Care and Use Committee (IACUC) were 
strictly followed.  
  
In Vitro Experiments  
 Mixed Lymphocyte Reactions (MLR) were used to examine regulatory T cell 
responses in vitro. Two mice were sacrificed to carry out each of these experiments. One 
mouse served as the regulatory and effector T cell donor, while the other provided 
antigen presenting cells (APCs). Auxiliary, brachial and mesenteric lymph nodes, as well 
as the spleen were excised from the T cell donor. Only the spleen was taken from the 
APC donor mice. Tissues were homogenized and antibodies added for staining purposes.  
MLR with GFP/RFP reporter mice 
 Foxp3.GFP-Cre.Rosa26.RFP (hereafter referred to as GFP/RFP) strain reporter 
mice are bred with knock-in green florescent protein (GFP) as a marker for gene 
expression of the foxp3 transcript. Red florescent protein (RFP) transgene is inserted into 
the Rosa26 locus and flanked by loxP sites. Mice that have both markers cannot express 
GFP without RFP. Therefore a mouse that is double positive for GFP and RFP expresses 
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the foxp3 transcript. A mouse that is only positive for RFP expresses the foxp3 transcript 
in the past, but does not do so currently. Foxp3 is considered to be a crucial protein for 
the function of regulatory T cells (Bailey-Bucktrout, 2013). Therefore, cells that are 
GFP+RFP+ represent regulatory T cells, while GFP-RFP+ cells are ex-regulatory T cells. 
GFP-RFP- cells were never regulatory and are characterized as effector T cells. 
 
Figure 5. Graphic representation of fluorescently labeled cell identities. Cells that are GFP+RFP+ are 
Tregs. Cells that are GFP-RFP+ are ExRegs. Cells that are GFP-/RFP- are T effector cells (original figure).  
  
 
T cells are harvested from GFP/RFP reporter mice by excising the spleen and 
lymph nodes. Spleen and lymph nodes are homogenized, washed and filtered to remove 
impurities and fat that may have been present on the tissue surface. APC/Alexa Fluor- 
647 anti-CD4 antibody was used to stain T cells. Anti-CD4 antibody is widely used as a 
marker for T helper cells and is known to exist on the surface of regulatory T cells. 
Antigen presenting cells were harvested from the spleens of either DBA/2J strain 
mice or non-expressing reporter mice. Spleens were homogenized, washed, and filtered 
to remove impurities and fat that may have been present on the tissue surface.  Staining 
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protocol incorporated the use of ACP/Alexa Fluor-647 anti-CD11c antibody, as well as 
PECy7 anti-CD11b antibody.  
After washing away excess antibody, 4',6-diamidino-2-phenylindole (DAPI) 
staining was applied to both antigen presenting cells and T cells. DAPI is a blue 
fluorescent dye that binds to adenine-thymine rich regions of DNA. Because DNA is 
generally only exposed during apoptotic and necrotic events, DAPI is used to label dead 
or dying cells. 
After staining with DAPI, the cells are ready to be sorted. Cells were sorted using 
flow cytometric analysis and a Becton Dickinson FACSAria™ III sorter. The antigen 
presenting cells were gated DAPI negative, CD11c high, and CD11b intermediate/high 
and then sorted. Regulatory T cells were gated DAPI negative, CD4 high, GFP high and 
RFP high and sorted. T effector cells were gated DAPI negative, CD4 high, GFP low and 
RFP low. The presence of GFP and RFP was identified with the use of fluorescein 
isothiocyanate (FITC) and DsRed flourochromes, respectively. Cells were sorted into T 
cell media for increased viability. T cell media was made from IMDM with 10% FBS and 
Penicillin-Streptomycin-L-glutamine.  
Once the cells had been sorted, they were centrifuged and brought into a sterile 
hood for plating. T cells were resuspended at a final concentration of 1,000 cells per 
microliter. Final concentration of antigen presenting cells was one cell per 10 microliters. 
Cells were plated using 300 microliter round-bottom wells. One hundred thousand T cells 
were plated with ten thousand antigen-presenting cells. Interleukin 2 (IL-2) at a 
concentration of 20 ng/ml was added to each well to allow for increased regulatory T cell 
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viability. Regulatory T cells were exposed to two treatments: one with 
Lipopolysaccharides (LPS), and the other without. LPS was added at a concentration of 1 
µg/ml. LPS is a large endotoxin found on the outer membrane of gram-negative bacteria, 
and used here to illicit an immune response.  
An alternative method used in the study was the use of anti-CD3/anti CD28 co-
stimulation. Anti-CD3 at a concentration of 2 µg/ml was used to coat flat-bottom well 
plates prior to addition of lymphocytes. After about four hours of anti-CD3 incubation, 
the wells were washed three times with phosphate buffered saline (PBS) and lymphocytes 
were added at the same concentration as stated above. In addition to IL-2 and LPS, anti-
CD28 was added at a concentration of 4µg/ml. A combination of anti-CD3 and anti-
CD28 antibodies has been shown to directly stimulate CD4+ and CD8+ T cell 
proliferation by mimicking the action of antigen presenting cells (Thomas et al., 2002). 
This protocol was used in the hopes of increasing T cell viability in vitro by inducing a 
more potent stimulation.  
Plated cells were allowed to incubate and later analyzed at the day 5 time point. 
On day 5, cell were gently extracted from wells and placed in test tubes. The cells were 
then washed and resuspended in PBS with 1% fetal bovine serum (FBS). Anti-CD4 APC 
antibody and DAPI were added for staining. Cells were then subject to flow cytometric 
analysis and sorted. Sorted ex-regulatory T cells were found by gating on CD4 high, 
DAPI low, GFP low and RFP high. T effectors were also sorted by gating on CD4 high, 
DAPI low, and GFP and RFP low.  Cells were sorted into lysis buffer and analyzed by 
single cell real-time PCR. The kit number used for the PCR is 46-7200. Cells were 
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analyzed for the presence of several transcription factors. GAPDH is a housekeeping 
gene used here to confirm the presence of a cell in each well. Wells lacking GAPDH 
were ignored. CD11C primer was added to eliminate dendritic cells from PCR analysis. 
RORγt, Tbet, and GATA3 were used to identify effector phenotypes. 
MLR with transgenic ABM x GFP/RFP reporter mice 
 In the initial mixed lymphocyte reactions of this study, regulatory T cell 
stimulation by the DBA/2J APCs was relatively low. T cell receptor (TCR) specificity of 
regulatory T cells is known to be relatively heterogenic; however, it was decided that this 
study would benefit from a more specific system. T cells of the ABM TCR transgenic 
mouse have a Vα2.1 and a Vβ8.1 T cell receptor specific for the I-ABM12 molecule, and 
will not respond to other alloantigen (Sanchez-Fueyo et al., 2006). The I-ABM12 antigen is 
expressed on the B6.C-H2BM12/KhEg, hereafter referred to as bm12, mouse strain, 
(Sanchez-Fueyo et al., 2006).  
 Breeding a Foxp3.GFP-Cre.Rosa26.RFP reporter mouse with an ABM TCR 
transgenic mouse made it possible to harvest TCR specific regulatory T cells that had 
reporter function. Breeding parental generations of these two mice theoretically results in 
100% of the F1 generation expressing the ABM transcript, while 56.25% will express the 
GFP/RFP reporter transcripts. In this model, T cells were taken from the GFP/RFP x 
ABM TCR transgenic mice, while antigen presenting cells were harvested from the bm12 
mouse strain. This model facilitates MHC class II specific binding between the ABM T 
cell receptor and the I-ABM12 antigen. This TCR specificity results in a much stronger 
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activation of regulatory T cell receptors, thereby increasing proliferation and viability of 
the cells of interest.   
 
 
Figure 6.  Mixed lymphocyte reaction model with TCR transgenic mouse model. ABM TCR 
transgenic mice were bred with GFP/RFP reporter mice to obtain T cells with greater TCR-antigen 
specificity. Antigen presenting cells were harvested from the bm12 mouse strain. These mice contain an I-
Abm12 antigen that specifically binds to the ABM T cell receptor (Original figure).  
 
 A slightly different staining protocol was used in this model. The day 1 staining 
remained the same for both the T cell and APCs. Vβ8 APC antibody was added to the 
day 5 protocol in order to positively identify cells that were bound to the bm12 antigen. 
In this model, ex-regulatory T cells were found by gating DAPI low, CD4 high, Vβ8 high 
and sorting the GFP low and RFP high population. This same gating protocol was used to 
identify regulatory T cells, except the sorted population consisted of GFP and RFP high 
cells.  
 
In Vivo Experiments 
 Mouse models were used to illustrate the response of regulatory T cells by 
transplanting pancreatic islet allograft tissue into GFP-RFP reporter mice. Foxp3.GFP-
Cre.Rosa26.RFP strain mice were used as transplant recipients, while pancreatic islets 
were isolated from mature DBA/2J strain mice. Five days prior to transplantation, 
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GFP/RFP reporter mice were given intraperitoneal injections of Streptozotocin (STZ) at 
0.01 ml per gram mouse. STZ is a toxin known to destroy insulin-producing beta cells of 
the pancreas. STZ was used in this model to induce symptoms of type 1 diabetes. This 
method made it possible to determine the success of the islet transplantation by 
monitoring the blood glucose levels of the animals after surgery.  
 Blood glucose monitoring began four days before the transplantation to insure 
that all mice had developed symptoms of T1D. Mice that had blood glucose levels above 
200 mg/dl were considered diabetic. Mice that had blood glucose levels of 500 mg/dl or 
higher were given either saline or insulin to ensure that they were healthy enough to 
undergo transplantation.  
  Allograft recipients were subject to four treatments:  
Treatment Group 1 Rapamycin + Anti-CD154 + TLR Agonist 
Treatment Group 2 Rapamycin + Anti-CD154 
Treatment Group 3 TLR Agonist Only 
Treatment Group 4 Untreated 
Table 2. Allograft recipients were subject to four different treatments (Original table). 
 
 
 The combination of rapamycin and anti-CD154 has been shown to be a powerful 
short-term inhibitor of pancreatic islet allograft rejection in non-human primates 
(Koulmanda, 2006). The success of this combination has sparked great interest in the 
scientific community with hopes of its application in humans. This study uses a 
rapamycin with anti-CD154 combination in order to maximize clinical relevance.  
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 Treatments began on the day of transplantation. Rapamycin was administered at a 
dose of 3 mg per kg body weight. 250 microliters of Anti-CD154 monoclonal antibody 
treatment was injected into each mouse. CpG and LPS were both injected at a dose of 50 
micrograms per gram mouse. Rapamycin was injected subcutaneously, while all other 
injections were administered intraperitoneally.  
 Rapamycin, anti-CD154, LPS, and CpG were administered daily for two days 
after treatment to their assigned treatment groups. On days three to six post-
transplantation, only rapamycin was administered. Mice were injected with an additional 
dose of rapamycin on day nine. Tissue harvesting and analysis occurred on day twelve 
post-transplantation. The kidney, and spleen were excised from the specimen for analysis. 
Single cell real-time PCR was used to determine phenotypic expression. . Kit number 46-
7200 was used for the PCR. Cells were analyzed for the presence of several transcription 
factors. As in the in vitro experiments, GAPDH was used to confirm the presence of a 
cell in each well. CD11c primer was added to eliminate dendritic cells from PCR 
analysis. RORγt, Tbet, and GATA3 were used to identify effector phenotypes. 
TLR Agonists 
 Lipopolysaccharides (LPS) and CpG oligodeoxynucleotides (CpG) were used as 
TLR agonists in this model. As mentioned earlier, LPS is a large endotoxin found on the 
surface of gram-negative bacteria. LPS works by binding to a TLR4-CD14 receptor 
complex on the surface of an antigen presenting cell. This binding activates protein 
tyrosine kinases (PTK) and leads to the mobilization of the NF-κB transcription factor 
(Ziegler-Heitbrock, 1995). CpG indirectly stimulates T cell activation by inducing type 1 
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interferon (IFN-1) production by antigen presenting cells (Sun et al., 1998). Once 
released into the circulation, IFN-1 binds to the type 1 interferon receptor on T cells and 
induces activation. 
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RESULTS 
 
In Vitro Experiments  
MLR using ABM x GFP/RFP Reporter Mice 
 
 Mixed lymphocyte reactions with this model had limited success due to 
difficulties in sorting an adequate number of regulatory T cells. For reasons unknown, 
these mice were consistently smaller than those of the GFP/RFP reporter strain and 
therefore had fewer regulatory T cells per mouse. It was never possible to analyze these 
cells with PCR due to low proliferation and very poor viability. Because of a ubiquitous 
lack of stimulation, most cells were found to be dead or dying by the day 5 sort.  
After spending several months breeding these mice and attempting to produce 
results, it was decided to abandon this model. Regulatory T cells only make up between 
about 5 to 10 percent of the total T cell population (Ahmadzadeh, 2015). This fact makes 
it relatively difficult to find and sort T cells in vitro. We felt that our best option was to 
continue by using the GFP/RFP strain model to maximize regulatory T cell numbers.  
 
MLR using GFP/RFP Reporter Mice 
 After several variations in technique, mixed lymphocyte reactions were 
successfully cultured and analyzed using this model. Regulatory T cell numbers obtained 
from these mice were relatively low as well.  
Figure 6 shows Regulatory T cell sort data for day 1. Dead cells were excluded by 
gating CD4 (APC) high and DAPI low.  The cell population that was sorted is shown in 
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the bottom right panel. These are the regulatory T cells, characterized as being double 
positive for GFP (FITC) and RFP (DsRed). Final count was 367,000 regulatory T cells 
sorted.  
 
Figure 7. Day 1 flow cytometry data for sorting regulatory T cells. Cells were gated for 
CD4+FITC+DsRed+ character and sorted (original figure).  
  
Dentritic cells (DC) were identified using flow cytometric analysis and sorted. 
Dead cells were excluded by gating for DAPI negative. The final sorted population is 
shown in the bottom right panel. The boxed region represents the dentritic cell 
population, identified as showing high expression for CD11c (APC) and high or 
intermediate expression for CD11b (PECy7). 100,000 dentritic cells were sorted and 
diluted to a concentration of 100 cells per microliter.  
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Figure 8. Day 1 flow cytometry data for sorting dentritic cells.  Cells were gated for DAPI-
CD11c+CD11b int/+ and sorted (original figure).  
Cells were plated so that each well received 10,000 DC’s and approximately 91,000 
regulatory T cells per well. Each well, already coated with anti-CD3 antibody, then 
received anti-CD28 and IL-2. Two wells received lipopolysaccharide while the remaining 
two did not receive any TLR agonist. The cells were left to incubate for five days and 
then analyzed and sorted. Sort data for day 5 is shown below. Tregs were sorted from 
both treatment groups (LPS+ and LPS-). Visual examination of the wells after 
incubation, as well as sort data indicated large amounts of proliferation. ExRegs were 
successfully identified by gating DAPI-CD4+GFP+/-RFP+. According to this model, a 
distinct ExReg population should be GFP- and RFP+. However, upon flow cytometric 
analysis, it was decided that the best course of action would be to sort the GFP+/- 
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population for single cell PCR. This decision was based on previous difficulties in sorting 
a proper cell count. There was also a lack of clear differentiation between the two 
populations. Cells were sorted directly into a 96 well plate at a rate of one cell per well. 
 
 
Figure 9. Flow cytometric data for single cell sort conducted after 5 days of cell cutlre. Data shown 
above is from treatment group with LPS. Tregs and ExRegs were sorted directly into a 96 well plate for 
singe cell PCR analysis. Cells were gated DAPI-CD4+GFP+/-RFP+ and sorted. Gating was identical for 
both LPS+ and LPS- treatment groups (original figure).  
 
Single Cell PCR 
Cells were successfully sorted into a ninety-six well plate and pre-amplified for 
cDNA replication. Wells that had either no GAPDH expression or showed expression for 
CD11c were eliminated, leaving eighty-seven wells for analysis. The transcription factor 
RORyt was not expressed in any well, suggesting that none of these cells had TH17 
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phenotypic expression.  The presence of Tbet was minimal, with only three wells 
expressing Tbet expression in the treatment group without LPS. TH2 phenotypic 
expression was therefore insignificant.  
GATA3 expression was relatively high in both treatment groups. Twenty-five 
wells from the group with LPS expressed GATA3, while eighteen did not. In contrast, 
only sixteen wells from the group without LPS contained GATA3, whereas twenty-eight 
did not. A chi-squared statistical analysis gave a p value equal to 0.0543 (p= 0.0543). 
This p value represents a likely significant difference in the number of wells expressing 
GATA3 in the treatment group with LPS, versus the group without. This finding suggests 
that the presence of lipopolysaccharide had a relatively significant impact in promoting 
the expression of the TH1 phenotype.  
 
Figure 10. Graphic representation of the number of cells that exhibit expression of GATA3 from 
each treatment group. The difference in the number of wells expressing GATA3 between each treatment 
group approached significance. The treatment group with LPS had a significantly greater number of wells 
expressing GATA3 (original figure).  
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The amount of GATA3 expressed by each cell was then compared between 
treatment groups. Each GATA3 expressing cell was standardized against its GAPDH 
expression, and a logarithmic value of relative expression was generated. These values 
were then plotted and analyzed for statistical significance. Fischer’s exact test was used, 
which generated a p value of 0.5, suggesting that there was no significant difference in 
amount of expression between treatment groups. Although the group treated with LPS 
showed a greater number of cells expressing GATA3, the difference in expression 
between the two groups was insignificant. 
                                          
Figure 11. Graphic depiction of the amount of GATA3 expression by cells between treatment groups. 
Although cells treated with LPS showed slightly higher expression of GATA3, the difference was not 
significant (original figure).  
 
 The expression of foxp3 was compared across treatment groups. The retention of 
Foxp3 expression was significantly greater in the treatment group with LPS. A chi 
squared statistical analysis of this finding generated a p value of 0.0009. In the treatment 
group with LPS, 34 cells retained expression of the foxp3 transcript, whereas just 9 cells 
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did not. In contrast, in the treatment group without LPS, 19 cells continued to express 
foxp3, while 25 did not.  
 
Figure 12. Retention of Foxp3 expression across treatment groups. A significantly greater number of 
Tregs in the treatment group with LPS retained foxp3 expression (p=0.0009). Cells in the treatment group 
without LPS tended to lose their foxp3 expression (original figure).  
 
 
In Vivo Experiment 
 This study’s in vivo experiments are still in progress. Four mice were given 
injections of streptozotocin and subsequently developed type 1 diabetes. Blood glucose 
levels were monitored closely to confirm symptoms of T1D. As of this writing, we are 
seven days post islet transplantation. Successful transplantation has been indicated by the 
return of all specimens’ blood glucose levels to normal range 36 hours post operation. 
This is the first round of in vivo experiments, so it was decided to start with just 
two of the four treatment groups. All four mice received Rapamycin and CD154. Two 
mice (one male, one female) were also given CpG and LPS as TLR agonists. This 
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correlates to treatments one and two, as stated previously in the methods section. TLR 
agonist was given to treatment group two on days zero (day of transplant) through two, as 
well as day five post operation. TLR agonist will also be administered on day 8 post-op, 
leading up to tissue harvest. Thus far, the mice are doing as expected and the experiment 
is progressing smoothly. 
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DISCUSSION 
 
 This project has established proof of principle by demonstrating a model that is 
effective for studying phenotypic changes in regulatory T cells (Tregs), both in vivo and 
vitro. This is the first study of its kind to specifically examine the effect that toll-like 
receptor (TLR) agonists have in promoting allograft rejection via their effects on 
regulatory T cells. The beneficial effects that rapamycin and CD154 have in promoting 
allograft acceptance have been well established; however, investigators have 
demonstrated conclusively that TLR agonists bypass the CD154-Rapamycin T cell 
activation blockade and cause allograft rejection. This is the first study that aims to 
elucidate the mechanism by which this happens in a diabetic mouse model. 
Regulatory T cells are historically difficult to study, mainly because of their 
minority presence and their instability in vitro. Most published studies that have 
elucidated much of what we know about regulatory T cells have come from in vivo 
models. This study demonstrates a successful and reliable protocol for studying Tregs in 
vitro. Interleukin-2 (IL-2) has been described as a cytokine necessary for Treg stability 
and long-term survival. We confirm that the addition of IL-2 results in much greater 
viability, enabling more dependable flow cytometric analysis and an increased cell count 
for sorting.  
 The choice to use single cell PCR, instead of pooled PCR, allowed for greater 
consistency in producing results. Our pooled real-time PCR protocol requires a minimum 
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of two hundred and fifty cells for reliable results. After incubation, staining, and lysis, 
that number proved difficult to obtain from one mouse. Single cell PCR, although more 
expensive, allows investigators to use just one mouse as a Treg donor and produces more 
consistent results.  
 As previously stated, our ABM x GFP/RFP mouse strain proved unsuccessful in 
producing results. Our hope was that the ABM-bm12 antigen specificity would result in 
increased proliferation, enabling the use of pooled real-time PCR; however, the low 
regulatory T cell number per mouse made this a challenge. We hypothesize that 
inheritance of the desired transgene led to the development of mice with stunted growth 
and less than a usable number of Tregs.  We predict that using two mice as Treg donors, 
instead of one, may resolve this problem; however, the time required for breeding made 
this option impractical.  
 This in vitro study using GFP/RFP reporter mice produced results using a 
consistently reproducible model. The results obtained from single cell PCR indicate a 
greater number of regulatory T cells expressing an effector phenotype in those treated 
with lipopolysaccharide (LPS). Specifically, the number of Tregs expressing GATA3 was 
higher in the LPS treatment group, compared to the group without LPS. This result 
indicates that the presence of LPS likely caused regulatory T cells to adopt a TH2 effector 
phenotype. As previously discussed, TLR agonists act on antigen presenting cells to 
directly upregulate expression of CD80/CD86 costimulatory molecules. In doing so, TLR 
agonists effectively bypass immunosuppressant drugs such as rapamycin or anti-CD154. 
The exact mechanism of regulatory T cell transdifferentiation into the TH2 phenotype by 
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way of TLR agonist is unclear. It is also yet to be determined whether TH2 will be the 
dominating phenotype in the in vivo model.  
 There was no significant difference in relative expression of GATA3 by cells 
across treatment groups. In other words, TH2 cells in the treatment group with LPS did 
not differ significantly in their amount of GATA3 expression from those that were not 
treated with LPS. This insignificance was not surprising and simply demonstrates that 
TH2 cells may have a basal amount of GATA3 expression, regardless of their 
environment. Of greater importance was the finding that LPS seems to trigger a response 
from Tregs, resulting in their transdifferentiation into a TH2 cell.  
It has been well established that a major role of TH2 cells is the production of 
interleukin 4 (IL-4). Through a positive feedback mechanism, this IL-4 production leads 
to greater TH2 proliferation (Brown, 2008). IL-4 has many functions that result in a more 
robust inflammatory response. One such function is the induction of monocyte-derived 
macrophages from the blood. In the presence of IL-4, these macrophages have been 
shown to proliferate and become active, leading to potential pathogenesis (Jenkins et al., 
2011). It has also been demonstrated that the presence of IL-4 prevents the formation of 
TGF-β-derived regulatory T cells. Instead, IL-4 induces proliferation of IL-9 and IL-10 
producing T effector cells, resulting in an even more robust inflammatory response 
(Dardalhon et al., 2009). Therefore, although TH2 by itself is a relatively benign 
inflammatory agonist, its presence indicates the possibility of slow-onset inflammation. 
In vivo, for example, this might result in chronic allograft rejection.  
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No RORγt expression was seen in any wells and an insignificant presence of Tbet 
was observed in three wells of the treatment group lacking LPS. This finding indicates 
that TLR-induced transdifferentiation of Tregs did not result in the appearance of TH1 or 
TH17 phenotypes. It is well established that TGF-β induces naïve T cells to adopt a 
regulatory phenotype. It is also known that TGF-β with the addition of IL-6 promotes the 
formation of highly potent TH17 inflammatory cells (Bettelli et al., 2006). Because of this 
common lineage, questions have been raised as to whether regulatory T cells have the 
ability to adopt a TH17 phenotype in certain immuno-environments. This in vitro model 
suggests that these lineages are distinct within the tested environment. 
An unexpected loss of foxp3 expression by regulatory T cells in the treatment 
group without LPS was observed. The foxp3 transcript is typical of the regulatory 
phenotype, and is usually lost upon differentiation. Furthermore, foxp3 expression has 
been shown to become unstable in pathogenic environments (Zhou et al., 2009). 
Therefore, our finding that regulatory T cells treated with LPS seemed to have more 
stable expression of foxp3 than in those without LPS was unexpected. This finding 
indicates that the loss of foxp3 expression is not necessary for regulatory T cells to adopt 
the TH2 phenotype.  
As stated previously, in vivo models for studying regulatory T cells are more 
reliable, and more accurately depict the natural immunophysiology of regulatory T cells. 
For this reason, moving forward the bulk of this project’s focus will be towards in vivo 
testing and results. Our in vivo models have progressed nicely and, as of this writing, are 
expected to produce results within the next week. The in vitro and in vivo models 
	  40 
discussed in this paper represent the groundwork for future testing. Several additional in 
vivo and in vitro experiments will be conducted to further this investigation.  
Single cell PCR panels will be expanded to include additional transcription 
factors and cytokines. Transcription factors may be added to the panel based on previous 
findings. For example, presence of IL-4 will be examined to determine whether GATA3 
expressing cells behave as natural TH2 cells. Future studies will utilize a larger cohort of 
animals in order to strengthen our statistical analyses. The focus of the experiments will 
gradually shift from in vitro to in vivo models in order to produce results consistent with a 
regulatory T cell’s natural environment. Additional analyses will include a comparison of 
regulatory T cell phenotypes to those expressed by T effectors. T effector transcription 
factor expression and production of cytokines will be compared to differentiated Tregs 
that are phenotypically similar. This type of analysis will be used to determine if, for 
instance, Treg-derived TH2 cells produce similar quantities of inflammatory cytokine as 
TH2 cells that were sorted from the T effector population. 
 
Conclusion  
In healthy individuals, the immune system is a carefully orchestrated balance 
between activation and suppression. Detriments to health associated with 
immunodeficiency and autoimmunity evidence the critical importance of maintaining this 
balance. As potent suppressors of immunoactivation, regulatory T cells play a critical role 
in preventing hyperactivity of our immune system. Examples of such hyperactivity 
include autoimmunity and allograft rejection. It has been demonstrated that maintaining 
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high numbers of regulatory T cells results in allograft tolerance. Furthermore, a common 
characteristic of autoimmunity is an imbalance between T effector and regulatory T cells, 
favoring the former. Therefore, regulatory T cells play pivotal roles in both the 
establishment and maintenance of self-tolerance.  
Despite major advances in the scientific community’s understanding of regulatory 
T cell immunophysiology, several setbacks have been met in attempting to utilize them 
for immunotherapy. Drugs such as Rapamycin and CD154 that are designed to halt T cell 
activation and boost regulatory T cell populations are rendered insufficient in the 
presence of toll-like receptor (TLR) agonists.  TLR agonists therefore result in 
immunoactivation and transdifferentiation of Tregs into effector T cell phenotypes.  
Our understanding of TLR receptors and pathways is substantial, however, 
relatively little research has been directed towards investigating their effects on 
regulatory T cell populations. This study’s primary goal was to broaden the current 
understanding of how TLR activation affects regulatory T cells. In doing so, we aimed to 
elucidate additional aspects of the TLR mechanisms that result in direct T cell activation 
and the reduction of Treg numbers. As the investigation moves forward, this will be 
accomplished by identifying expression of transcription factors and signaling molecules 
that is initiated upon TLR activation. Our finding that the presence of TLR agonists likely 
result in the adoption of a TH2 effector phenotype by regulatory T cells is a step towards 
meeting this goal. It is expected that our in vivo models will elucidate further phenotypic 
shifts of regulatory T cells associated with the activation of toll-like receptors. It is our 
hope that a comprehensive understanding of TLR-induced effects on regulatory T cell 
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expression will result in the development of more effective drug models for inducing 
tolerance. Such drugs will likely work by stopping TLR activation from bypassing 
therapeutic blockades meant to bolster regulatory T cell populations. Such drug therapy 
would represent major progress in transplant research and will likely pave the way for 
dramatically increased rates of allograft acceptance.  
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